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Abstract
This study analyses the priorities of public donors in funding HIV prevention by either integrated condom
programming or HIV preventive microbicides and vaccines in the period between 2000 and 2008. It further
compares the public funding investments of the USA government and European governments, including the EU,
as we expect the two groups to invest differently in HIV prevention options, because their policies on sexual and
reproductive health and rights are different. We use two existing officially UN endorsed databases to compare the
public donor funding streams for HIV prevention of these two distinct contributors. In the period 2000-2008, the
relative share of public funding for integrated condom programming dropped significantly, while that for research
on vaccines and microbicides increased. The European public donors gave a larger share to condom programming
than the United States, but exhibited a similar downward trend in favour of funding research on vaccines and
microbicides. Both public donor parties invested progressively more in research on vaccines and microbicides
rather than addressing the shortage of condoms and improving access to integrated condom programming in
developing countries.
Background
The number of people living with HIV worldwide has
continued to grow, reaching 33.4 million in 2008. In the
same year 2.7 million new HIV infections occurred,
almost half (45%) among people younger than 25 years
[1]. Despite a more than eight-fold increase of total glo-
bal financing for fighting AIDS, from 1.6 billion US$ in
2001 to 13.8 billion in 2008, a small fraction has gone to
HIV prevention [2]. Public donor expenditures for treat-
ment have grown much faster than the spending for pre-
vention [3-5]. The two largest public AIDS funds, the
Global Fund for HIV Tuberculosis and Malaria (GFATM
initiated in 2001) and the Presidents’ Emergency Pro-
gramme for AIDS (PEPFAR since 2003), spend about
70% and 80% of their respective HIV budgets on treat-
ment and care programmes in developing countries [6,7].
However, as of December 2008, mainly due to the high
costs of treatment, 58% of those infected and requiring
antiretroviral treatment cannot access such treatment [1].
Prevention, to halt the increase in new infections, there-
fore, remains as urgent as before. HIV experts currently
agree that prevention is underfunded [3]. Therefore,
insight into how the limited public funding for preven-
tion is distributed is important.
At the end of 2008, for every two people starting anti-
retroviral treatment, five were newly infected [1]. Even if
there were a cure for HIV, treatment only would by no
means suffice to control the epidemic [8]. Although, HIV
infection is avoidable, HIV prevention interventions are
estimated to be accessible to fewer than one in five peo-
ple worldwide [9]. Similarly, less than 40% of young peo-
ple in developing countries are estimated to have basic
information about AIDS and HIV prevention [1]. This
knowledge gap might be due to the frequently expressed
objections of political and religious leaders to sexual
behavioural change programmes known to reduce HIV
infection rates, such as integrated condom programming
[10]. The same leaders, however, seem to be eager to wel-
come donor support to antiretroviral treatment for their
populations [10]. The knowledge gap on prevention is
reproduced on another level. Only a limited number of
studies provide information on the coverage level of HIV
* Correspondence: a.peters@rng.nl
1Institute for Gender Studies, Radboud University Nijmegen, Netherlands
Full list of author information is available at the end of the article
Peters et al. Globalization and Health 2010, 6:23
http://www.globalizationandhealth.com/content/6/1/23
© 2010 Peters et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
prevention programmes in different developing countries
[4], while ample data are available on the coverage rates
of treatment and care programmes [1]. Public funders
could play a crucial role in supporting developing coun-
tries to extend the coverage of evidence-based HIV pre-
vention programmes. So might private and philanthropic
donors, but due to lack of information on these funding
streams they are excluded here from the analysis.
Within HIV prevention, different approaches can be
distinguished, such as prevention by vaccines or microbi-
cides, prevention by integrated condom programming,
and some recently introduced prevention technologies
such as male circumcision and prophylactic use of antire-
troviral drugs. Prevention by vaccines or microbicides has
been considered an important means to stop the AIDS
epidemic since the beginning of the 21st century.
Recently, the director of UNAIDS expressed his belief,
that a preventive HIV vaccine holds the greatest opportu-
nity for ending the epidemic and many share his view
[11]. Several scientists, however, among them the chief
editor of the Lancet, seriously question the possibility of
developing a successful HIV preventive vaccine and criti-
cise the overly optimistic prospect portrayed by the vac-
cine research community [12]. In 2007, five large-scale
HIV vaccines studies were stopped because they failed to
show satisfactory results [13]. In the same year, two
microbicides trials were halted because they led to more
HIV infections instead of less [14]. In 2009, vaccine
researchers reported some success in a trial in Thailand,
but the observed vaccine efficacy was too modest to be of
any public health significance [15]. In 2010, microbicide
researchers reported a first success in a trial in South
Africa. Women who used the, to be tested microbicide
were 39 percent less likely to become infected with HIV
than women who received a placebo gel [16]. However,
the consequences of these recent findings for prevention
schemes are not clear yet and currently under discussion.
Consequently, these technologies still are being
researched and have not yet been applied in HIV preven-
tion programmes. This means that the funding directed
to this category of HIV preventives totally goes to
research rather than to application in HIV prevention
programmes, and therefore has not yet a direct effect on
prevention.
Another HIV prevention technology is condoms and
integrated condom programming. In contrast to vaccines
and microbicides, male condoms have existed since at
least 1000 BC. Female condoms, which are as effective as
male condoms, have existed since 1984, and were offi-
cially approved by the United States Food and Drug
Administration (US FDA) in 1993 [17,18]. In 2009,
UNAIDS, WHO and UNFPA renewed their joint posi-
tion statement on condoms: “The latex condom is the
single, most efficient, available technology to reduce the
sexual transmission of HIV” [19]. Empirically, its cost-
effectiveness in comparison to other HIV prevention
methods has been proven [20,21]. Female and male
condoms are central to efforts to halt the spread of HIV.
This was officially recognized as early as 1994 in the Pro-
gramme of Action of the International Conference on
Population and Development [22]; again in 2001 in the
Political Declaration of commitment on HIV/AIDS in the
United Nations General Assembly Special Session
(UNGASS) on HIV/AIDS [23]; and again in 2005 as part
of a plan to achieve the Millennium Development Goals
[24]. The female condom in particular is currently the
only technology that gives women greater control over
protecting themselves from HIV, other STIs and unin-
tended pregnancy [25,26].
Integrated condom programming is essential to the
realisation of sexual and reproductive health and rights,
including the prevention of HIV [27-29]. Integrated
means that the programme is delivering two or more
types of services previously provided separately, as a sin-
gle, coordinated, and combined service. Examples are
condom programming combined with counselling
services on family planning, or with HIV/STI testing
services or with sexuality education [30]. Integrated con-
dom programming has proven to be successful, under
the condition that a gender, relational and community
perspective is used [31,32]. And that the condoms are
affordable. Cost studies have shown that the consumer
price of condoms has a strong effect on access and, thus,
usage [33]. Integrated programmes, which subsidise or
freely distribute condoms, have led to increased usage, a
condition for effectiveness in HIV prevention [34]. In
July 2010, during the last international AIDS conference
in Vienna, UNAIDS reported on successes in HIV pre-
vention by integrated condom programming in a multi
country study [35]. At the same conference, a researcher
from John Hopkins University showed convincing results
of declining HIV infection rates in countries with gener-
alised HIV epidemics. These declines occurred in a time
when antiretroviral treatments were not yet available and
when priority was on prevention through sexual beha-
vioural change programmes combined with unproble-
matic access to condoms [36]. It is beyond the scope of
this article to discuss the factors leading to successful
condom programming in-depth. However, it is important
to recognise that it is an evidence-based, cost-effective,
efficient, and directly available way of delivering HIV pre-
vention services to people.
Apart from the two above mentioned prevention
approaches, three other HIV prevention technologies
were introduced in some developing countries such as
male circumcision [37], use of anti-retroviral drugs in
pregnancy to prevent mother to child transmission
(PMCT) [38], or prophylactic use of antiretroviral drugs
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(PreP) [39]. All three technologies will only be partly
efficacious for preventing sexual transmission of HIV.
Circumcised men may still contract HIV (and other
STI’s), and can still pass it on to their next partner,
making protection with condoms still necessary and
thus, the need for integrated condom programming.
The need for protection also remains when introducing
PMCT or PreP. There is still much discussion on the
assessment of the effectiveness of the various HIV pre-
vention technologies. The assessment varies with the
researchers’ disciplinary perspective. Kippax concluded
in her study that the (bio-) medical sciences are domi-
nant in the discussion on HIV prevention, leaving hardly
any space for social sciences [40]. In this article, we will
not address the different scientific interpretations in
HIV prevention effectiveness, since this is done recently
by Heise et al [41]. We will focus on the funding choices
being made in HIV prevention. Our first question is
therefore: How is the public funding from USA and
Europe for HIV prevention divided over research on
HIV preventive vaccines and microbicides and inte-
grated condom programming in the period 2000 to
2008?
We are particularly interested in the funding choices
in HIV prevention, taken by two different public donors,
the USA government, and European governments,
including the EU. The European public donors have a
long tradition of supporting gender and sexual and
reproductive health and rights as part of Official Devel-
opment Aid [42,43]. The following statement on HIV
prevention of the Council of the European Union illus-
trates its position:
We re-affirm our commitment to tackle the HIV
pandemic in a comprehensive and integrated way
and in particular the HIV prevention gap. We are
profoundly concerned about the resurgence of par-
tial or incomplete messages on HIV prevention,
which are not grounded in evidence and have lim-
ited effectiveness. We, the European Union, firmly
believe that HIV prevention must utilise all
approaches known to be effective, like universal
access to sexual and reproductive health information
in accordance with the international decisions at the
International Conference on Population and Devel-
opment agenda and reliable access to essential sexual
and reproductive health commodities, including
male and female condoms [44].
The European donors thus clearly recognise the
importance of sexual and reproductive health and rights,
and explicitly state the necessity to provide reliable
access to male and female condoms. In contrast, the
USA government failed to set up a holistic sexual and
reproductive health and rights approach in development
aid. In the period between 2000 and 2008, especially
with the Bush presidency, it has implemented a conser-
vative HIV policy leading to a global anti-condom
movement [45,46], started earlier by the Catholic
Church. Because of this difference in policy, we expect
to find that the European governments and the EU give
a larger share of the funding to integrated condom pro-
gramming in the period 2000 - 2008 than the USA. Our
second question therefore is: Is there a difference in
public donor funding within HIV prevention between
the EU and the USA?
Methods
We compare the actual amounts and relative share of
public funding by the USA and Europe for two cate-
gories of HIV prevention. This comparison limits itself
to public funds donated to HIV prevention by donor
governments, i.e. public donors. Private and philanthro-
pic donors are not included in our study for several rea-
sons. Firstly, the public donors have a responsibility to
take measures for HIV prevention and for the develop-
ment of HIV prevention technologies. New HIV tech-
nologies are mainly being developed with public sector
financing and not private sector funding [41]. Secondly,
public donors are primarily accountable in relation to
the effectiveness and efficiency in HIV prevention, espe-
cially under Official Development Aid (ODA). Data
availability is a third reason. While data on public fund-
ing are relatively easily detectable, data on private funds
are scattered and no integrated database exists contain-
ing all the foundations active in the field. Public donors
are primary donors. These primary donors provide the
basic information for our study. We review actual donor
government expenditures in support of HIV prevention
for two groups of primary donors, i.e. European govern-
ments including the European Commission, and the
USA. The funding comes directly from these public
funding agencies, and is directed to research bodies and
international development assistance agencies.
This study is based on secondary analysis, using infor-
mation from two available databases, of which UNAIDS
endorses one and UNFPA the other [47,48]. We did not
gather new data, but categorise, compare and analyse
existing data.
Tracking donor government financing for HIV vac-
cines and microbicides is relatively easy since these two
prevention methods are still in the stage of research and
not in delivery and, thus, are not yet part of daily pro-
gramming. It is relatively easy to classify financial sup-
port to research and trials, which have a clear start and
ending. Computing donor government funding levels for
integrated condom programming is more complicated,
because of its integration in different programmes and
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services. Condoms offer dual protection: against
unwanted pregnancy and against sexually transmitted
infections. Consequently, integrated condom program-
ming is an essential component of family planning,
reproductive health, and AIDS interventions. In our
study, we do not distinguish financial flows for inte-
grated condom programming used for family planning
and reproductive health purposes from those used for
HIV prevention, as we will elaborate below.
The data on funding for research on HIV vaccines and
microbicides are collected on an annual basis by the HIV
Vaccine Microbicide Resource Tracking Group, which
consists of three organisations: the HIV Vaccine Advo-
cacy Coalition (AVAC), the Alliance for Microbicide
Development (AMD), and the International HIV Vaccine
Initiative (IAVI) supported by UNAIDS [47]. To analyse
the financial resource flows for integrated condom pro-
gramming, we used the database of the UNFPA/NIDI
project “Financial Resource Flows for Population and
HIV activities” as a source http://www.resourceflows.org.
This project monitors the global financial flows allocated
to sexual and reproductive health and rights, including
AIDS, to assess the fulfilment of commitments made at
the International Conference on Population and Devel-
opment (ICPD) Programme of Action, in 1994, and at
the UNGASS on HIV/AIDS in 2001, as described earlier.
On an annual basis, UNFPA/NIDI report and present
their data to the UN Secretary-General [48]. The
UNFPA/NIDI database, like the one from the HIV Vac-
cine Microbicide Resource Tracking Group, tracks finan-
cial resource flows of primary donors, among others.
Their data are comparable because they both use the
same definition and categorisation of donors. Moreover,
both databases make use of the same research methodol-
ogy, surveying donors by using self-administered stan-
dard questionnaires about their funding streams.
However, calculating the exact funding for condom pro-
gramming from the UNFPA/NIDI database was not self-
evident, because condoms are often an integrated part of
a project and thus calculation of funding levels for inte-
grated condom programming requires certain estimates.
We used the following approach to reach the best
estimates.
In the UNFPA/NIDI questionnaire, donors categorise
their funding in line with that of the 1994 and subsequent
ICPD programmes of action as follows: family planning,
AIDS, reproductive health, and basic research. Integrated
condom programming can be part of any of these four
categories. By far the majority of projects are classified as
mixtures, meaning that they fall in two or more of the
four categories, expressed in percentages. Thus, we con-
sidered all four categories equally to find the total funding
for integrated condom programming. The UNFPA/NIDI
database contained 6,707 projects in 2000, which increased
to 15,098 projects in 2008 (Table 1. Column A). The total
amount of funding increased from 1,887 million US$ in
2000 to 10,778 million in 2008 (Table 1. Column B). To
establish the integrated condom projects, we counted the
number of projects with the word “condom(s)” and “con-
traceptive(s)” in the project title and/or in the project
description, which typically summarizes the project in
about 300 words. We assumed that if there is no mention
of “condom(s)” or “contraceptive(s)” in the title or descrip-
tion of a particular project, condom programming is
not part of the project. This resulted in 294 projects in
2000 and 68 in 2008 (Table 1. Column C), and total
amounts of funding of 189 m US$ and 42 m US$, respec-
tively (Table 1. Column D). Among the total number of
projects, there were many without or with a very short
project description of less than 50 characters, and thus
with a little chance of including the words “condom(s)” or
“contraceptive(s)”. We therefore discarded all these pro-
jects and only took into account the projects with a full
project description of more than 50 characters, which had
a sufficient chance to contain the words “condom(s)” or
“contraceptive(s)” and describe the integration of condoms
in the project (Table 1. Column E). For each year, we cal-
culated the proportion of the projects with either one of
these words by dividing column C (number of projects
with “condom(s)” or “contraceptive(s)” in the title or
description) by column E (total number of projects with a
project description of more than 50 characters) and multi-
plied by 100 to find the percentages (Table 1. Column F).
We multiplied this percentage with the total amount of
public donor expenditure on family planning, AIDS,
reproductive health and basic research (Column B),
assuming that the projects without any project description,
or a very short one, were similar to the projects with
descriptions.
The figures presented in Column G are currently the
best available estimates for the total public donor expen-
ditures for integrated condom programming. We use
these figures to compare the funding streams of the EU
and USA on integrated condom programming. Still, one
should be aware of the assumptions made in calculating
these figures and consider that we are interested in the
observed trends, rather that the precise data for a parti-
cular year.
Since we estimated the volume of integrated condom
programming, we considered it important to add
sources for counterchecking these estimates. Addition-
ally, we studied the global trends in donor purchases of
condoms in the period 2000 - 2008 by using the
annually produced UNFPA reports called “Donor sup-
port for contraceptives and condoms for STI/HIV pre-
vention” [25]. This report is based on a database
produced by the commodity management branch of
UNFPA, which directly collects data from donors on the
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procurement and international transport of condoms.
http://rhi.rhsupplies.org. However, this database is not
suitable to compare data between the USA and Europe,
because it does not make a clear distinction between
primary and secondary donors. This latter group
includes for example international NGOs, whose fund-
ing originates from primary donors, making original
funding from USA or European governments indistin-
guishable. We also compare our results with the esti-
mated shortages of condoms in developing countries, as
described in literature.
Results
Figure 1 shows the amounts and trends in donor gov-
ernment financing for our two categories of HIV pre-
vention: ‘vaccines and microbicides’ and ‘integrated
condom programming’ by primary donors: the govern-
ments of Europe, including the EU, and the government
of the USA.
Both Europe and USA increased funding to research into
vaccines and microbicides between 2000 and 2008. The
USA has constantly and steeply increased their funding to
research into vaccines and microbicides, from 307 m US$
in 2000 to 799 m US$ in 2007, and a slight decrease in
2008 to 774 m US$. A constant rise in funding for this sec-
tor is also evident for Europe: from 24 m US$ in 2000 to
139 m US$ in 2007, and a slight decrease in 2008 to 109 m
US$. Moreover, USA funding to research in vaccines and
microbicides is significantly higher than European funding.
Both Europe and USA decreased funding to integrated
condom programming in the period 2000-2008, in a simi-
lar way and Figure 1 does not show any difference in these
two trend lines. They are rather overlapping. USA and Eur-
ope gave about the same amount of funds to integrated
condom programming, although irregular. The USA
decreased their funding between 2000 and 2008 from 79 m
to 40 m US$. In 2008, funding was about 50% under the
level of 2000. European governments decreased their fund-
ing to the delivery of integrated condom programming
from 90 m US$ in 2000 to 33 m US$ in 2008 and, like the
USA, in 2008 ended under the level of 2000. Figure 1 also
shows that financing priorities of governments in Europe
have shifted from integrated condom programming to
research into vaccines and microbicides between 2003 and
2004. It also shows that 2008 might be the beginning of a
shift towards slightly increased investments in integrated
condom programming.
For a further interpretation of the quantity of public
donor expenditures by Europe and the USA, it is impor-
tant to consider the size of the respective populations and
economies. Between 2000 and 2008, the countries that
had the largest contributions to the total of sexual and
reproductive health and rights including AIDS were the
United Kingdom, the Netherlands, Norway, Denmark, Fin-
land, and Sweden, each contributing between 400 and 800
US$ per million dollars of gross national income (GNI)
[49]. Within Europe, there are also differences. Norway
contributes almost four times as much as Italy, despite
having a six times smaller economy. The Netherlands con-
tributes more than six and half times as much as France,
although its economy is less than a third of that of France
[42]. The American government gave about half of the
average amount of European countries: between 200 and
400 US$ per million dollars of GNI [49].
Figure 2 shows that, Europe shows a similar decrease in
the share of funding to implementation of integrated
condom programming as the USA: the share of funding
to integrated condom programming by Europe decreased
from 79% to 23% between 2000 and 2008. The share of
funding to integrated condom programming by the USA
decreased, with fluctuations, from 20% to 5%. Our results
show a turning point in 2004 in funding practices for the
Table 1 Estimating public donor expenditures for integrated condom programming 2000 - 2008 using UNFPA/NIDI
database (million US$)
A B C D E F G
Year Total #
of
projects
Total
amount
(m US$)
# Projects with
“condom(s)” or
“contraceptives” in
project title/
description
Total funding of projects
with “condom(s)” or
“contraceptives” in title/
description
(m US$)
# Projects with
project
description of
>50 characters
% Projects with
“condom(s)” or
“contraceptives” in
title/description
Estimated amount
spent on
integrated condom
programming
(m US$)
2000 6,707 1,887 294 189 2,456 12.0 226
2001 7,421 2,103 153 135 2,388 6.4 135
2002 8,610 3,225 168 129 2,911 5.8 186
2003 11,079 3,845 116 59 1,503 7.7 297
2004 8,981 4,813 81 65 2,865 2.8 136
2005 11,576 6,891 133 123 2,885 4.6 318
2006 18,522 7,381 93 110 5,714 1.6 120
2007 13,860 8,806 25 83 8,904 0.3 25
2008 15,098 10,778 68 42 7,936 0.9 92
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European governments: before 2004, the majority of
funding goes to integrated condom programming while
after 2004 research into vaccines and microbicides
increasingly receives more. It is noteworthy that Europe
shows a similar sharp reduction of their financial support
of condom programming as the USA and its conservative
condom sentiments.
Our countercheck, described in our methods para-
graph reveals the global trends in total donor funding
for male and female condoms in the period 2000 - 2008,
as shown in Figure 3.
2000 2001 2002 2003 2004 2005 2006 2007 2008
Europe: condom programming 90 40 61 131 62 119 54 11 33
Europe: vaccines and microbicides 24 32 44 55 87 125 139 139 109
USA: condom programming 79 61 56 140 51 139 41 9 40
USA: vaccines and microbicides 307 375 451 542 608 676 784 799 774
0
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900
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Europe: condom programming Europe: vaccines and microbicides
USA: condom programming USA: vaccines and microbicides
Figure 1 Trends in donor expenditures for vaccines and microbicides vs. for integrated condom programming from Europe and the
USA 2000 - 2008 (m US$).
2000 2001 2002 2003 2004 2005 2006 2007 2008
Europe: condom programming 79 56 58 70 42 49 28 7 23
USA condom programming 20 14 11 20 8 17 5 1 5
Europe: vaccines and microbicides 21 44 42 30 58 51 72 93 77
USA: vaccines and microbicides 80 86 89 80 92 83 95 99 95
0
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80
100
2000 2001 2002 2003 2004 2005 2006 2007 2008
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Europe: condom programming Europe: vaccines and microbicides
USA condom programming USA: vaccines and microbicides
Figure 2 Relative share of funding for vaccines and microbicides vs. for integrated condom programming by governments from
Europe and USA 2000 - 2008 (%).
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Donor expenditure on male condoms is relatively con-
stant over these nine years, on female condoms increas-
ing. Our observed trend in decreased funding for
integrated condom programming is not contradictory to
the trend in total donor funding for only the purchase
of male and female condoms. Most years the funding
spent on integrated condom programming is 2 to 4
times more than the money spent on the purchase of
condoms. This means that programming costs are 2 to
4 times the costs of buying the commodities. Our
results also match a same type of trend in global con-
dom shortfalls as analysed in a few other studies [25,50].
A global condom shortage existed before 2000 and sus-
tained during the period under research. UNFPA calcu-
lated a shortfall of 7 billion male condoms in developing
countries in 2000 [51] increasing to 16 billion in 2006,
mainly due to increased population figures [52]. The
global shortfall of condoms exists despite an increased
provision of condoms by the private sector. Middle
income countries such as Brazil, China, India, and South
Africa do not depend on foreign public donors for their
condom supply, unlike some low income developing
countries [53-55]. We did not observe a significant
increase in public donor support for integrated condom
programming in relation to this existing and increasing
condom shortfall. The current shortfall of the female
condom is much higher than of the male condom [26].
Above data shows some increased funding for female
condoms, but this amount remains minimal in relation
to the rest of the amounts.
Discussion
Our study leads to a new insight in the trends in public
funding on HIV prevention. There is a remarkable shift
away from supporting low cost and effective technolo-
gies to funding the research into as of yet not proven
high technology HIV preventives. Moreover, our expec-
tation that the European donors let themselves be
guided by their sexual and reproductive health and
rights policies and their claims for universal access to
condoms, proved incorrect. Unexpectedly, they have
decreased their relative share of funding to condom pro-
gramming in times that the AIDS problem exploded
further. It looks as if the European public donors now
follow the American prevention agenda and move away
from the 1994 programme of action of the ICPD, speci-
fically from its integrated condom programming [56,57].
Although, we are not in a position to fully discuss the
determining factors behind the found public funding
trends on HIV prevention, we like to consider a few.
This enables the readers to place our findings in a
broader context. One such factor might originate from
the 2001 United Nations General Assembly Special Ses-
sion (UNGASS) on HIV/AIDS. This assembly ended
with a declaration of commitment on HIV/AIDS [23].
Afterwards, UNAIDS developed indicators, aimed to
monitor global progress on this declaration of which
only one is related to HIV prevention: “the level of pub-
lic sector investment in research and development
(R&D) for HIV vaccines and microbicides” [58]. Refer-
ence to fund other HIV prevention strategies, such as
2000 2001 2002 2003 2004 2005 2006 2007 2008
Male condoms 46 91 76 65 72 76 69 84 66
Female condoms 0 2 3 3 6 5 9 13 14
0
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50
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Male condoms Female condoms
Figure 3 Trends in total donor expenditures for male and female condoms 2000 - 2008 based on UNFPA database (m US$).
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integrated condom programming is absent. We assume
that this global indicator made American and European
donors alike raise investments in research into vaccines
and microbicides.
The position taken by UNAIDS, the global lead agency
on AIDS, might also contribute to diminishing invest-
ment in integrated condom programming by the Eur-
opean donors. Although UNAIDS mentions condom
promotion in its HIV prevention policy, it does not
prioritise or highlight integrated condom programming
[56]. Even the most recently published UN progress
report “Scaling up priority HIV/AIDS interventions in
the health sector” totally ignores integrated condom
programming [57]. Indeed other researchers earlier
pointed to the weak promotion of condoms by
UNAIDS. They literally speak about “the virtual disap-
pearance of condom promotion in UNAIDS literature
and campaigns” [4].
Another factor, mentioned in recent studies [59], is
the influence of philanthropic donor organisations on
public donors. Specifically, the priorities of the biggest
private AIDS donor organisation in the USA, the Bill
and Melinda Gates Foundation (BMGF), might have an
impact on government funding policies. Globally, USA
government and BMGF account for 79% of the global
funding for vaccines and for 59% of the global funding
for microbicides [47]. The two agencies have a same
type of HIV prevention funding focus, namely new, bio-
medical technologies, such as vaccines and microbicides
[59].
Our findings clearly demonstrate a global under-
exploitation of integrated condom programming, a phe-
nomenon heavily debated in the context of global health
governance [60,61]. Some scholars link such priority
shift in funding HIV prevention to economic and scien-
tific interests of the donors [62,63]. Recipients of fund-
ing for integrated condom programming are above all
the governments of developing countries or NGOs [48].
Recipients of funding for vaccines and microbicides, are
primarily privately owned medical pharmaceutical com-
panies or scientific research institutes based in North
America and Western Europe, with associations in
developing countries [62,63]. Illustrative is also the title
of the new annual report of HIV Vaccines and Microbi-
cides Resource Tracking Working Group: “Advancing
the Science in a Time of Fiscal Constraint: Funding for
HIV Prevention Technologies in 2009” [47]. The
advancement of science clearly is different from the
advancement of HIV prevention in the context of devel-
opment assistance. In terms of official development
assistance, concern is expected to be with women and
men in developing countries who daily run the risk of
infection and urgently need access to low cost and effec-
tive HIV preventive means and programming. They
should not be left in the cold with only the promise of a
forthcoming ‘biomedical magic bullet to solve HIV’.
Other scholars have noted a bias in favour of biomedical
research rather than an investment into socio-cultural
studies that re-examine sexuality and gender relations to
better implementation of condom programming [40,62].
Further research into the power and gender issues that
are at play in the decision-making on public funding for
HIV prevention is necessary.
Conclusion
The governments of the USA and Europe (European
countries and the EU) both shifted their attention from
funding of integrated condom programming to research
into new prevention technologies, such as vaccines and
microbicides. We revealed a disturbing unexpected
trend in funding from the group of European public
donors in contrast with their fierce fight for the ICPD
programme of action of 1994. The tendency that Ameri-
can and European donors are both increasingly reluctant
to commit sufficient funds for sexual and reproductive
health and rights has been concluded earlier [63]. Our
study adds the revealing conclusion that the European
donors have relatively cut funding on integrated con-
dom programming to the same extent as the USA.
Recommendations
We recommend that public funders aim at a clear
insight in the funding trends and reflect on the conse-
quences of the shifts in these trends and what they actu-
ally mean for the people in need for HIV prevention.
We recommend that increasing funds for developing
one type of HIV preventive should not be detrimental
to the support for another, an already effective means of
protection, as long as these are not yet generally avail-
able and accessible. Public funders should better realise
that education and access to condoms remain a central
priority issue in HIV prevention.
We recommend that public funders who like to
adhere to sexual and reproductive health and rights
policies not only monitor and extend funding for inte-
grated condom programming, but also show the value
of sociological research for the successful implementa-
tion of HIV prevention and integrated condom
programming.
Further research is necessary to understand better why
public donors make certain funding choices on HIV
prevention for developing countries, and particularly to
assess how power and gender issues are involved in
decision making on funding for HIV prevention.
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